ASH 2021 | Ibrutinib, rituximab and venetoclax in the treatment of patients with newly diagnosed MCL
In this video, Michael Wang, MD, University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of a Phase II Window-2 clinical trial, which analyzed the safety and efficacy of ibrutinib, rituximab and venetoclax in patients with mantle cell lymphoma (MCL) (NCT03710772). Dr Wang briefly explains the impressive responses observed in the patient cohorts in this trial, and the importance of transitioning from a chemotherapy-based regimen to a chemotherapy-free regimen in the treatment of newly diagnosed MCL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
Disclosures
Miltenyi Biomedicine GmbH: Consultancy, Honoraria; Bayer Healthcare: Consultancy; CStone: Consultancy; Celgene: Research Funding; Molecular Templates: Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Dava Oncology: Honoraria; Hebei Cancer Prevention Federation: Honoraria; Imedex: Honoraria; AstraZeneca: Consultancy, Honoraria, Research Funding; Epizyme: Consultancy, Honoraria; VelosBio: Consultancy, Research Funding; Mumbai Hematology Group: Honoraria; BGICS: Honoraria; Oncternal: Consultancy, Research Funding; Kite Pharma: Consultancy, Honoraria, Research Funding; DTRM Biopharma (Cayman) Limited: Consultancy; The First Afflicted Hospital of Zhejiang University: Honoraria; Lilly: Research Funding; BeiGene: Consultancy, Honoraria, Research Funding; Anticancer Association: Honoraria; Juno: Consultancy, Research Funding; BioInvent: Research Funding; Loxo Oncology: Consultancy, Research Funding; Scripps: Honoraria; Physicians Education Resources (PER): Honoraria; OMI: Honoraria; Pharmacyclics: Consultancy, Research Funding; Newbridge Pharmaceuticals: Honoraria; Acerta Pharma: Consultancy, Honoraria, Research Funding; CAHON: Honoraria; Chinese Medical Association: Honoraria; Clinical Care Options: Honoraria; Moffit Cancer Center: Honoraria; Genentech: Consultancy; InnoCare: Consultancy, Research Funding.
